Lapchak PA - Search Results

1

Genome response to tissue plasminogen activator in experimental ischemic stroke.

Jickling GC, Zhan X, Ander BP, Turner RJ, Stamova B, Xu H, Tian Y, Liu D, Davis RR, Lapchak PA, Sharp FR. Jickling GC, et al. Among authors: lapchak pa. BMC Genomics. 2010 Apr 21;11:254. doi: 10.1186/1471-2164-11-254. BMC Genomics. 2010. PMID: 20406488 Free PMC article.

2

Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model.

Chapman DF, Lyden P, Lapchak PA, Nunez S, Thibodeaux H, Zivin J. Chapman DF, et al. Among authors: lapchak pa. Stroke. 2001 Mar;32(3):748-52. doi: 10.1161/01.str.32.3.748. Stroke. 2001. PMID: 11239197

3

The phenylpropanoid micronutrient chlorogenic acid improves clinical rating scores in rabbits following multiple infarct ischemic strokes: synergism with tissue plasminogen activator.

Lapchak PA. Lapchak PA. Exp Neurol. 2007 Jun;205(2):407-13. doi: 10.1016/j.expneurol.2007.02.017. Epub 2007 Mar 16. Exp Neurol. 2007. PMID: 17439814

4

Comparison of the post-embolization effects of tissue-plasminogen activator and simvastatin on neurological outcome in a clinically relevant rat model of acute ischemic stroke.

Guluma KZ, Lapchak PA. Guluma KZ, et al. Among authors: lapchak pa. Brain Res. 2010 Oct 1;1354:206-16. doi: 10.1016/j.brainres.2010.07.050. Epub 2010 Jul 29. Brain Res. 2010. PMID: 20673757 Free PMC article.

5

Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: a combination therapy study with tissue plasminogen activator.

Lapchak PA. Lapchak PA. Brain Res. 2010 Jan 14;1309:136-45. doi: 10.1016/j.brainres.2009.10.067. Epub 2009 Nov 3. Brain Res. 2010. PMID: 19891959

6

Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke.

Lapchak PA, Chapman DF, Zivin JA. Lapchak PA, et al. Stroke. 2000 Dec;31(12):3034-40. doi: 10.1161/01.str.31.12.3034. Stroke. 2000. PMID: 11108768

7

The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke.

Lapchak PA, Araujo DM, Song D, Zivin JA. Lapchak PA, et al. Stroke. 2002 Jan;33(1):147-52. doi: 10.1161/hs0102.100530. Stroke. 2002. PMID: 11779904

8

Advances in ischemic stroke treatment: neuroprotective and combination therapies.

Lapchak PA, Araujo DM. Lapchak PA, et al. Expert Opin Emerg Drugs. 2007 Mar;12(1):97-112. doi: 10.1517/14728214.12.1.97. Expert Opin Emerg Drugs. 2007. PMID: 17355216 Review.

9

Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6, 6-tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: combination studies with the thrombolytic tissue plasminogen activator.

Lapchak PA, Chapman DF, Zivin JA. Lapchak PA, et al. Stroke. 2001 Jan;32(1):147-53. doi: 10.1161/01.str.32.1.147. Stroke. 2001. PMID: 11136930

10

Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator.

Lapchak PA, Zivin JA. Lapchak PA, et al. Stroke. 2003 Aug;34(8):2013-8. doi: 10.1161/01.STR.0000081223.74129.04. Epub 2003 Jul 10. Stroke. 2003. PMID: 12855833

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

168 results

Search Page

Filters